Commentary

Taking cardiac pacing from boring to super cool


 

The barriers to getting more CSP trials

The challenge going forward will be funding new trials. CSP stands to prevent pacing-induced cardiomyopathy and offer less costly alternatives to standard biventricular pacing for CRT. This is great for patients, but it would mean that fewer higher-cost CRT devices will be sold.

Heart rhythm research is largely industry-funded because in most cases better therapies for patients mean more profits for industry. In the case of CSP, there is no such confluence of interests.

Conduction system pacing has come about because of the efforts of a few tireless champions who not only published extensively but were also skilled at using social media to spread the excitement. Trials have been small and often self-funded.

The data presented at HRS provides enough equipoise to support a large outcomes-based randomized controlled trial. Imagine if our CSP champions were able to find public-funding sources for such future trials.

Now that would be super cool.

Dr. Mandrola practices cardiac electrophysiology in Louisville, Ky., and is a writer and podcaster for Medscape. He participates in clinical research and writes often about the state of medical evidence. He has disclosed no relevant financial relationships. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA approves Fitbit’s AFib-detection software
MDedge Cardiology
Empagliflozin rapidly improves acute heart failure symptoms in hospitalized patients
MDedge Cardiology
COVID-19 cardiovascular complications in children: AHA statement
MDedge Cardiology
New smart device shows highly accurate AFib detection: mAFA II
MDedge Cardiology
Young and older athletes show similar arrhythmia patterns with fQRS
MDedge Cardiology
Study points to causal role for Lp(a) in atrial fibrillation
MDedge Cardiology
Will you have cardiac arrest? New tech may predict if and when
MDedge Cardiology
Cutting dementia risk in atrial fibrillation: Does rhythm control strategy matter?
MDedge Cardiology
Cutting dementia risk in AFib: Does rhythm control strategy matter?
MDedge Cardiology
Antithrombotic therapies shifting for Watchman LAA occlusion
MDedge Cardiology